Cupedo Lab
Translational research into multiple myeloma
Tom (T.) Cupedo
E-mail: t.cupedo@erasmusmc.nl
X: @TCupedo
Scopus: link
Contact:
Leenke de Jong-de Visser, secretary, m.dejong-devisser@erasmusmc.nl
The myeloma Research Lab combines molecular stratification of multiple myeloma patients to predict disease course, therapy response and relapse with mechanistic studies into the pathobiology of myeloma development, progression and immunogenicity. All our studies are closely aligned with ongoing clinical trials (see also P. Sonneveld) and are supported by experimental models for mechanistic interventions.
See also www.BMbrowser.org for interactive browsing of scRNAseq datasets.
Our research
Bone marrow immune environment
The goal of this research line is to identify immunological alterations resulting from multiple myeloma development, and use this knowledge to design novel therapies and identify biomarkers for immunotherapy efficacy. To do so, we are charting the immune system in multiple myeloma patients at the single cell level by multi-color flow cytometry, single cell RNAsequencing and in vitro functional studies. Potential targets are tested in animal models of multiple myeloma to unravel their mechanisms of action.
Bone Marrow stromal environment
In the bone marrow, multiple myeloma cells are embedded in a niche defined by mesenchymal stromal cells, endothelial cells and immune cells. The non-hematopoietic stromal and endothelial cells provide survival and proliferation signals to the tumor cells, and are thought to be important determinants of the therapy responsiveness of multiple myeloma cells. Even though the functional importance of the non-hematopoietic niche is well established, the identity of the myeloma-supportive niche cells and the mechanistic underpinnings of this support are less well clarified.
We have set up analyses pipelines to identify and characterize alterations in non-hematopoietic niche cells in multiple myeloma patients. We use single cell sequencing, multicolor flow cytometry and 3D culturing to identify and mechanistically interrogate primary stromal cells from myeloma patients. Experimental models of multiple myeloma allow us to unravel the importance of niche-derived signals for multiple myeloma disease progression and therapy response.
See also www.BMbrowser.org for interactive browsing of scRNAseq datasets.
Circulating Tumor Cells
Careful analyses of peripheral blood of multiple myeloma patients has revealed the presence of tumor cells in circulation. Understanding the composition and biological mechanisms of circulating myeloma cells could allow for disease monitoring and tumor cell analyses using peripheral blood, without the need for invasive bone marrow sampling.
Our team
Tom Cupedo, principal investigator
Natalie Papazian, research technician
Elodie Stoetman, bioinformatician
Antoine Domenger, Postdoc
Marjolein Appelman, PhD student
Luca Bertamini, PhD student
Marnix Koops, PhD student
Özge Erdem, intern
Suzanne Ho-Sam-Sooi, intern
Key publications
Hofste Op Bruinink D, Kuiper R, van Duin M, Tom Cupedo, van der Velden VHJ, Hoogenboezem R, van der Holt B, Beverloo HB, Valent ET, Vermeulen M, Gay F, Broijl A, Avet-Loiseau H, Munshi NC, Musto P, Moreau P, Zweegman S, van de Donk NWCJ, Sonneveld P. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. J Clin Oncol. 2022 Sep 20;40(27):3132-3150
Fokkema C, Moreau P, Van der Holt B, Lambert J, Van Duin M, Wester R, Jongen JLM, Van Doorn PA, Godet S, Jie KS, Fitoussi O, Delforge M, Keita-Manta A, Luycx O, Tom Cupedo, Van de Donk NWCJ, Zweegman S, Vermeulen JT, Sonneveld P, Broijl A. Treatment emergent peripheral neuropathy in the CASSIOPEIA trial. Haematologica. 2022 Jul 1;107(7):1726-1730
de Jong MME, Kellermayer Z, Papazian N, Tahri S, Hofste Op Bruinink D, Hoogenboezem R, Sanders MA, van de Woestijne PC, Bos PK, Khandanpour C, Vermeulen J, Moreau P, van Duin M, Broijl A, Sonneveld P, Tom Cupedo. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat Immunol. 2021 Jun;22(6):769-780